S030 A New Paradigm in the Management of the Hidradenitis Suppurativa Disease Spectrum
DESCRIPTION
This session will provide dermatologists with a complete framework with end-to-end practical decision-making ability to manage patients with HS across the spectrum of disease, inclusive of medical and procedure-based strategies. Discussion of novel concepts in the management of HS supporting this framework will include the following as examples: defining early and moderate disease which determines real-world eligibility for targeted treatments; assessing adequacy of initial treatment approach and timing treatment switches; evaluating for disease progression; and choosing off-label strategies having proof of concept to manage recalcitrant disease.
LEARNING OBJECTIVES
Classify patients with early and moderate disease to determine optimal treatment strategy
Describe a practical framework to assess initial treatment adequacy, disease progression, as well as the need and timing to modify therapy
Design a management strategy that incorporates advanced medical therapies, office-based and OR procedures, or sound off-label strategies for progressive or recalcitrant disease
SCHEDULE
9:00 AM
Defining mild and at least moderate disease with assignment of treatment class
9:30 AM
Treatment of at least moderate Hidradenitis Suppurativa
10:15 AM
Treatment Success and Inadequacy: defining the target of treatment, minimal disease activity, and disease progression
10:45 AM
Treatment modification and off-label approaches: what to do when goals of therapy are not met
11:15 AM
Application of office-based procedures to complement medical therapies
11:40 AM
Moderated Discussion
DIRECTOR
Amit Garg, MD, FAAD
SPEAKERS
Jennifer Lin Hsiao, MD, FAAD
John Ingram, PhD, MD
Christopher John Sayed, MD, FAAD
DISCLOSURES
Amit Garg, MD, FAAD
AbbVie – Advisory Board(Honoraria); Almirall – Consultant (1099 relationship)(Fees); Incyte Corporation – Advisory Board(Honoraria); Insmed Incorporated – Consultant (1099 relationship)(Honoraria); Novartis – Consultant(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding); Sanofi – Data Safety Monitoring Board(Fees); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Fees); UCB – Consultant(Honoraria); Zura Bio – Consultant (1099 relationship)(Fees);
Jennifer Lin Hsiao, MD, FAAD
AbbVie – Consultant(Fees), Speaker(Fees); Aclaris Therapeutics Inc. – Consultant (1099 relationship)(Fees); Amgen – Investigator(Grants/Research Funding); Astra Zeneca – Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Fees); Galderma – Speaker(Fees); Incyte – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Insmed – Consultant (1099 relationship)(Fees); Leo Pharma – Consultant (1099 relationship)(Fees); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Consultant(Fees), Speaker(Fees); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Pfizer Inc. – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Speaker(Fees); UCB – Consultant(Fees), Speaker(Fees);
John Ingram, PhD, MD
AbbVie – Consultant(Honoraria); Bluefin Biomedicine – Consultant (1099 relationship)(Honoraria); Boehringer Ingelheim – Consultant(Honoraria); British Journal of Dermatology – Other(Honoraria); Cantargia – Consultant (1099 relationship)(Honoraria); ChemoCentryx – Consultant(Honoraria); Citryll – Consultant(Honoraria); Elasmogen – Consultant (1099 relationship)(Honoraria); Engitix – Consultant (1099 relationship)(Honoraria); Incyte – Consultant (1099 relationship)(Honoraria); Indero, Inc. – Consultant (1099 relationship)(Honoraria); InflaRx – Consultant (1099 relationship)(Honoraria); Insmed Incorporated – Advisory Board(Honoraria); Kymera Therapeutics – Advisory Board(Honoraria); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Honoraria); Novartis – Consultant(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Honoraria); UCB – Consultant(Honoraria); Union Therapeutics – Consultant (1099 relationship)(Honoraria); Viela Bio – Advisory Board(Honoraria);
Christopher John Sayed, MD, FAAD
AbbVie – Advisory Board(Fees), Investigator(Fees), Speaker(Fees); Alumis – Consultant(Fees); AstraZeneca – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); ChemoCentryx – Investigator(Grants/Research Funding); Elasmogen – Consultant (1099 relationship)(Fees); Eli Lilly – Stockholder Public Company(Stock); Incyte – Consultant (1099 relationship)(Fees); Incyte Corporation – Investigator(Grants/Research Funding); InflaRx – Consultant(Fees), Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Investigator(Fees), Speaker(Honoraria); Sandoz Pharmaceuticals AG – Consultant (1099 relationship)(Honoraria); Sanofi – Consultant (1099 relationship)(Fees); UCB – Advisory Board(Honoraria), Consultant(Fees), Investigator(Grants/Research Funding);